Select the region that best fits your location or preferences.
This setting controls the language of the user interface, including buttons, menus, and all site text. Select your preferred language for the best browsing experience.
Select the languages for job listings you want to see. This setting determines which job advertisements will be displayed to you.
This is a unique position for a highly motivated and ambitious candidate, available at the Laboratory of Cell Stress & Immunity (CSI) in KU Leuven, for a research project focussed on creating next-generation of precision immunotherapy against metastatic colorectal cancer (CRC).
The CSI Laboratory is headed by Prof. Abhishek D. Garg and focusses on using novel reverse translational approaches powered by multi-omics and spatial mapping to solve cancer immunology & immunotherapy mysteries. Ultimately, the CSI lab aims to specialize in creating next-generation cancer immunotherapies to hasten progress in immuno-oncology and help improve therapeutic outlook for cancer patients, in close collaboration with leading researchers, immunologists, and oncologists, in Belgium and abroad. The CSI lab focusses on following (specific) research themes: cancer immunology & immunotherapy, immunology of cancer cell death, cross-species reverse translational immunology, stress or therapy-elicited immune-signaling pathways, immune cell biology, systems medicine, artificial intelligence (AI)-based immunology and biomarkers for clinical immuno-oncology.
CSI Lab regularly publishes in high-impact journals (e.g., Nature Medicine, Nature Rev Immunol, Science Advances, Science Transl Medicine), and has successfully pursued ground-breaking research that has led to high-impact valorisation (e.g., patents, initiation of early phase clinical trials and creation of spin-off company trajectories).
This project aims to utilize novel insights recently gained on targeting immuno-resistant CRC in the CSI lab and convert these into tangible precision immunotherapies for treating metastatic CRC with a clear mechanism-of-action and a tangible route toward future clinical translation. The project will integrate advanced immuno-oncology, multi-omics workflows, and translational immunotherapy. With this project we ambitiously aim to go significantly beyond the current state-of-the-art, by creating innovative immunotherapies that would be eventually ready-to-use in a clinic.
Website unit
https://gbiomed.kuleuven.be/english/research/50000618
For more information please contact prof. dr. Abhishek Garg, tel.: +32 16 37 93 40, mail: abhishek.garg@kuleuven.be. Official application should be entered via the above KU Leuven application portal.
KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.
KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.
Visit the employer page